

# ARDS: new considerations for a new definition

Giacomo Bellani, MD, PhD  
University of Milan-Bicocca, A.O. San Gerardo  
Monza (Italy)



@Gicobellani

# Conflicts of Interest

## ➤ INSTITUTIONAL:

- Research grants from: Draeger

## ➤ PERSONAL

- Consultancy fee from: Draeger, Dimar, Medtronic, Flowmeter
- Patent pending onflow generator for CPAP
- Lecturing fees: Draeger, GE Healthcare, Getinge, Intersurgical

# What is a «definition»?

- ✓ to state or set forth the meaning of (a word, phrase, etc.)
- ✓ to explain or identify the nature or essential qualities of

# Challenges to Berlin definition

Brings under same  
Umbrella vary different  
patients (from Malaria  
to pancreatitis)

Syndrome, not a  
disease!

Not  
sensitive/specific  
of DAD

Not always  
applicable!

Mortality is  
affected by many  
other factors!

$PaO_2/FiO_2$  depends  
on the conditions you  
measure it!

# The «kigali» definition of ARDS

	Berlin Criteria	Challenges in Resource Poor Settings	Kigali Modification of the Berlin Criteria
<u>Timing</u>	Within 1 wk of a known clinical insult or new or worsening respiratory symptoms	None	Within 1 wk of a known clinical insult or new or worsening respiratory symptoms
<u>Oxygenation</u>	$PaO_2/FiO_2 \leq 300$	Scarcity of arterial blood gas diagnostics	$SpO_2/FiO_2 \leq 315$
<u>PEEP requirement</u>	Minimum 5 cm H <sub>2</sub> O PEEP required by invasive mechanical ventilation (noninvasive acceptable for mild ARDS)	Scarcity of mechanical ventilators	No PEEP requirement, consistent with AECC definition
<u>Chest imaging</u>	Bilateral opacities not fully explained by effusions, lobar/lung collapse, or nodules by chest radiograph or CT	Scarcity of chest radiography resources	Bilateral opacities not fully explained by effusions, lobar/lung collapse, or nodules by chest radiograph or ultrasound
<u>Origin of edema</u>	Respiratory failure not fully explained by cardiac failure or fluid overload (need objective assessment, such as echocardiography, to exclude hydrostatic edema if no risk factor present)	None	Respiratory failure not fully explained by cardiac failure or fluid overload (need objective assessment, such as echocardiography, to exclude hydrostatic edema if no risk factor present)

Riviello, Kiviri, Twagirumugabe, *et al.*: Incidence and Outcomes of ARDS in Rwanda

Am J Respir Crit Care Med Vol 193, Iss 1, pp 52–59, Jan 1, 2016

# PEEP and stratification of outcome

Coppadoro et al. *Crit Care* (2021) 25:80  
<https://doi.org/10.1186/s13054-021-03502-y>

Critical Care



RESEARCH

Open Access



## Helmet CPAP to treat hypoxic pneumonia outside the ICU: an observational study during the COVID-19 outbreak

Andrea Coppadoro<sup>1</sup>, Annalisa Benini<sup>1</sup>, Robert Fruscio<sup>1,2</sup>, Luisa Verga<sup>1</sup>




# When should we diagnose ARDS?



ORIGINAL



## Resolved versus confirmed ARDS after 24 h: insights from the LUNG SAFE study

Fabiana Madotto<sup>1,2</sup>, Tàì Pham<sup>2,3,4</sup>, Giacomo Bellani<sup>5,6</sup>, Lieuwe D. Bos<sup>7</sup>, Fabienne D. Simonis<sup>7</sup>, Eddy Fan<sup>8,9</sup>, Antonio Artigas<sup>10</sup>, Laurent Brochard<sup>2,3,4</sup>, Marcus J. Schultz<sup>7,11</sup>, John G. Laffey<sup>2,3,4,12,13\*</sup>  and LUNG SAFE Investigators and the ESICM Trials Group

*Intensive Care Med* (2018) 44:564–577  
<https://doi.org/10.1007/s00134-018-5152-6>



# ACUTE RESPIRATORY DISTRESS SYNDROME IN ADULTS


By D.G. Ashbaugh et al. The Lancet, 1967

**“THE CLINICAL PATTERN, ... INCLUDES SEVERE DYSPNOEA, TACHYPNOEA, CYANOSIS THAT IS REFRACTORY TO OXYGEN THERAPY, LOSS OF LUNG COMPLIANCE, AND DIFFUSE ALVEOLAR INFILTRATION SEEN ON CHEST X-RAYS”**

...to explain or identify the nature or essential qualities of...



# Why are we so confused when it comes to ARDS definition?






## ARDS Berlin definition

*The ARDS Conceptual Model.* The panel agreed that ARDS is a type of acute diffuse, inflammatory lung injury, leading to increased pulmonary vascular permeability, increased lung weight, and loss of aerated lung tissue. The clinical hallmarks are hypoxemia and bilateral radiographic opacities, associated with increased venous admixture, increased physiological dead space, and decreased lung compliance. The morphological hallmark of the acute phase is diffuse alveolar damage (ie, edema, inflammation, hyaline membrane, or hemorrhage).<sup>29</sup>




José A. Lorente  
Pablo Cardinal-Fernández  
Diego Muñoz  
Fernando Frutos-Vivar  
Arnaud W. Thille

## Acute respiratory distress syndrome in patients with and without diffuse alveolar damage: an autopsy study



# ARDS from Berlin to Kigali. Where next?



# Other «directions»?

Aggregate on “broad” clinical aspects  
*Hypoxaemia requiring PPV*




*Defined based on “biological mechanisms”*

# «Unilateral» respiratory failure vs ARDS («bilateral»)

## Outcome of acute hypoxaemic respiratory failure: insights from the LUNG SAFE Study

*Eur Respir J* 2021; 57: 2003317


Tài Pham<sup>1,2,3,4</sup>, Antonio Pesenti<sup>5,6</sup>, Giacomo Bellani<sup>7,8</sup>, Gordon Rubenfeld<sup>9,10,11</sup>



# «Unilateral» respiratory failure vs ARDS («bilateral»)

2 c

No difference in severity or management




2 Quadrants-Unilateral




	Patients	Unilateral-infiltrate with two quadrants	Bilateral with two quadrants (ARDS)	p-value
<b>Oxygenation and ventilation</b>				
$P_{aO_2}/F_{iO_2}$ mmHg	1094	185±63	178±66	0.196
Mild	1094	56 (32.6)	318 (34.5)	0.509
Moderate		91 (52.9)	446 (48.4)	
Severe		25 (14.5)	158 (17.1)	
$P_{aO_2}$ mmHg	1084	46±15	44±13	0.134
pH	1084	7.33±0.12	7.34±0.11	0.148
$F_{iO_2}$	1094	0.5 (0.4–0.8)	0.5 (0.4–0.7)	0.247
Tidal volume mL·kg <sup>-1</sup> PBW	1046	7.6±1.8	7.8±1.7	0.153
Respiratory rate breaths·min <sup>-1</sup>	1091	20±6	20±6	0.444
Minute ventilation L·min <sup>-1</sup>	1071	10.33±4.50	10.31±4.62	0.942
PEEP cmH <sub>2</sub> O	1094	6.0 (5.0–10.0)	8.0 (5.0–10.0)	0.101
Plateau pressure cmH <sub>2</sub> O	336	20.8±5.8	21.8±5.4	0.238
Driving pressure cmH <sub>2</sub> O	336	13.1±5.9	14.1±4.9	0.282
PIP cmH <sub>2</sub> O	1056	25.9±8.2	25.7±8.0	0.847

p=0.794 for ventilation discontinuation




# Relationship between Driving Pressure and Mortality in Ventilated Patients with Heart Failure: A Cohort Study


Qilin Yang , Jiezhao Zheng , Xiaohua Chen, Weiyan Chen, Deliang Wen,



## Potentially modifiable factors contributing to outcome from acute respiratory distress syndrome: the LUNG SAFE study

John G. Laffey<sup>1,2\*</sup> , Giacomo Bellani<sup>3,4</sup>, Tàì Pham<sup>5,6,7</sup>, Eddy Fan<sup>8,9</sup>, Fabiana Madotto<sup>10</sup>, Ednan K. Bajwa<sup>11</sup>,

*Intensive Care Med* (2016) 42:1865–1876  
DOI 10.1007/s00134-016-4571-5





# PEEP changes and mortality

Yehya N, Ann Am Thorac Soc Vol 18, No 5, pp 857–864, May 2021

Association between driving pressure and development of postoperative pulmonary complications in patients undergoing mechanical ventilation for general anaesthesia: a meta-analysis of individual patient data



Ary Serpa Neto, Sabine NT Hemmes, Carmen SV Barbas, Martin Beiderlinden, Ana Fernandez-Bustamante, Emmanuel Futier, Ognjen Gajic, Lancet Respir Med 2016







Claude Guérin  
Taylor Thompson  
Roy Brower

## The ten diseases that look like ARDS

### Implications for treatment

If a patient with one of these ten ARDS mimics requires mechanical ventilation, there may be a substantial risk of ventilator-induced lung injury because inflammatory processes increase the vulnerability of the lung parenchyma to mechanical stress. Moreover, the volume of aerated lung is reduced, making the aerated lung vulnerable to overdistension. Therefore, we recommend using a lung-protective approach, as in ARDS, with an initial tidal volume goal of approximately 6 ml/kg predicted body weight [12]. The optimal level of positive end-expiratory

# Other «directions»?

Aggregate on “broad” clinical aspects  
*Hypoxaemia requiring PPV*



*Defined based on “biological mechanisms”*

# Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials



*Lancet Respir Med* 2014;  
2: 611-20

*Carolyn S Calfee, Kevin Delucchi, Polly E Parsons, B Taylor Thompson, Lorraine B Ware, Michael A Matthay, and the NHLBI ARDS Network*

A  
1.0  
— Phenotype 1  
— Phenotype 2

	ARMA cohort			ALVEOLI cohort		
	Phenotype 1 (n=318)	Phenotype 2 (n=155)	p value	Phenotype 1 (n=404)	Phenotype 2 (n=145)	p value
Mortality (at 90 days)	23%	44%	0.006	19%	51%	<0.001
Ventilator-free days	17.8	7.7	<0.001	18.4	8.3	<0.001
Organ failure-free days	14.5	8.0	<0.001	16.5	8.4	<0.001

Values are estimated means that take into account the uncertainty of class membership.


**Table 4: Association between phenotype assignment and clinical outcomes, adjusted for degree of uncertainty regarding phenotype assignment**

# Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial



Carolyn S Calfee, Kevin L Delucchi, Pratik Sinha, Michael A Matthay, Jonathan Hackett, Manu Shankar-Hari, Cliona McDowell, John G Laffey, Cecilia M O'Kane, Daniel F McAuley, on behalf of the Irish Critical Care Trials Group

Lancet Respir Med 2018;  
6: 691-98





Number at risk

No. at Risk					
Simvastatin	259	238	217	208	202
Placebo	280	250	231	220	205

Jean-Marie Forel  
Christophe Guervilly  
Sami Hraiech  
François Voillet

## Type III procollagen is a reliable marker of ARDS-associated lung fibroproliferation



# Proposal for the «Marion Island» definition....

**AHRF**

PaO<sub>2</sub>/FiO<sub>2</sub><300  
PEEP > 5  
Some infiltrates

Name

Mild

Moderate

Severe

12/24 hrs?

Severity layer

300 mmHg

200 mmHg

120 mmHg

Cardiac

Septic

Auto  
Immune

Etiology Layer

Hypo-

Hyper-

Inflammatory Layer

# Example 1: study on NIV

**AHRF**

Name

**Mild**

**Moderate**

**Severe**

Severity layer

300 mmHg

200 mmHg

120 mmHg

**Cardiac**

**Septic**


**Auto  
Immune**

Etiology Layer

**Hypo-**

**Hyper-**

Inflammatory Layer



# Example 2: study on Anti-inflammatory drug

**AHRF**

Name

**Mild**

**Moderate**

**Severe**

Severity layer

300 mmHg

200 mmHg

120 mmHg

**Cardiac**

**Septic**

**Auto  
Immune**

Etiology Layer

**Hypo-**

**Hyper-**

Inflammatory Layer



# “ARDS” since Berlin: new considerations for a new definition

- If ARDS=DAD, should we abandon the idea of diagnosing it with clinical criteria?
- Reappraise the concept of AHRF as a useful concept to study interventions beneficial to all these patients.
- Target with drugs specific biological mechanisms, identified by biomarkers?



@Gicobellani